Sinovac has received a revised Drug Supplementary Application Approval from the China State Food and Drug Administration (SFDA) for Panflu(TM), its pandemic influenza vaccine.
Under the revised approval, the age group eligible for use of the whole viron inactivated pandemic influenza vaccine was expanded to 18 years old and over, whereas it was previously 18 to 60 years of age, enabling Sinovac to reach a much broader percentage of the population.
Sinovac also received approval to change the existing packaging of 0.5mL to 1mL per vial, which will improve the company’s packaging capacity and put in a better position to deliver on its first order from the Beijing government.
Sinovac is currently focused on production of a vaccine against the new pandemic influenza strain, H1N1. This vaccine will be sold under the Panflu brand, which has in the past also referred to Sinovac's vaccine against the pandemic influenza strain, H5N1.
Sinovac expects to complete production of its first batch of the H1N1 Panflu vaccine by the end of July 2009.
No comments:
Post a Comment